Ablative radiotherapy for ultracentral lung cancers: Dosimetric, geometric, and volumetric predictors of outcomes and toxicity

被引:18
作者
Breen, William G. [1 ]
Jeans, Elizabeth B. [1 ]
Gergelis, Kimberly R. [1 ]
Garces, Yolanda, I [1 ]
Park, Sean S. [1 ]
Merrell, Kenneth W. [1 ]
Peikert, Tobias D. [2 ]
Mansfield, Aaron S. [3 ]
Wigle, Dennis A. [4 ]
Harmsen, William S. [5 ]
Ellerbusch, David C. [1 ]
Olivier, Kenneth R. [1 ]
Lucido, J. John, III [1 ]
Owen, Dawn [1 ]
机构
[1] Mayo Clin, Dept Radiat Oncol, 200 First St SW, Rochester, MN 55905 USA
[2] Mayo Clin, Div Pulm & Crit Care Med, Rochester, MN 55905 USA
[3] Mayo Clin, Div Med Oncol, Rochester, MN 55905 USA
[4] Mayo Clin, Div Thorac Surg, Rochester, MN 55905 USA
[5] Mayo Clin, Dept Biomed Stat & Informat, Rochester, MN 55905 USA
关键词
Ultracentral; Radiation; SBRT; RADIATION; SBRT;
D O I
10.1016/j.radonc.2021.03.001
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Ultracentral lung cancers arise near the proximal bronchial tree (PBT), trachea, or esopha-gus, and have been associated with worse outcomes and increased toxicity after radiotherapy. We sought to associate dosimetric and anatomic factors with oncologic outcomes and toxicities. Methods: One-hundred ten patients treated with ablative, curative-intent radiotherapy for ultracentral, node-negative, non-small cell lung cancer were included. Dosimetric and geometric data obtained using custom software that calculated volumes of target structures and organs-at-risk and measured the short -est vector length between these volumes were associated with outcomes and toxicity. Results: Common dose/fractionation schemes included 50 Gy in 5 fractions (57%), 60 Gy in 8 fractions (15%), and 48 Gy in 4 fractions (13%). Overall survival at 1, 2, and 5 years was 78%, 57%, and 32%, respectively. Factors significantly associated with death included endobronchial tumor, gross tumor volume (GTV) or planning target volume (PTV) contacting PBT, shorter distance from GTV to PBT or esophagus, volume of PBT receiving prescription dose, higher pericardium max dose, lung V20Gy, and mean lung dose. Local progression at 1, 2, and 5 years was 4%, 16%, and 21%. Factors associated with local progres-sion were lower GTV minimum dose and higher GTV/PTV volume ratio. Acute and late grade 2 + toxicity was seen in 18% and 27%, respectively. Four patients (4%) had fatal toxicity. Conclusions: Lower GTV minimum dose and smaller volumetric PTV expansions may increase risk of local progression, and should be balanced against normal tissue doses including pericardium maximum dose, lung V20Gy, and mean lung dose. (c) 2021 Elsevier B.V. All rights reserved. Radiotherapy and Oncology 158 (2021) 246-252
引用
收藏
页码:246 / 252
页数:7
相关论文
共 19 条
[1]  
[Anonymous], 2020, LUNG CANC ATLASES TE
[2]   Long-term Clinical Outcomes and Safety Profile of SBRT for Centrally Located NSCLC [J].
Arnett, Andrea L. H. ;
Mou, Benjamin ;
Owen, Dawn ;
Park, Sean S. ;
Nelson, Katy ;
Hallemeier, Christopher L. ;
Sio, Terence ;
Garces, Yolanda, I ;
Olivier, Kenneth R. ;
Merrell, Kenneth W. .
ADVANCES IN RADIATION ONCOLOGY, 2019, 4 (02) :422-428
[3]   Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trial [J].
Ball, David ;
Mai, G. Tao ;
Vinod, Shalini ;
Babington, Scott ;
Ruben, Jeremy ;
Kron, Tomas ;
Chesson, Brent ;
Herschtal, Alan ;
Vanevski, Marijana ;
Rezo, Angela ;
Elder, Christine ;
Skala, Marketa ;
Wirth, Andrew ;
Wheeler, Greg ;
Lim, Adeline ;
Shaw, Mark ;
Schofield, Penelope ;
Irving, Louis ;
Solomon, Benjamin .
LANCET ONCOLOGY, 2019, 20 (04) :494-503
[4]   Safety and Efficacy of a Five-Fraction Stereotactic Body Radiotherapy Schedule for Centrally Located Non-Small-Cell Lung Cancer: NRG Oncology/RTOG 0813 Trial [J].
Bezjak, Andrea ;
Paulus, Rebecca ;
Gaspar, Laurie E. ;
Timmerman, Robert D. ;
Straube, William L. ;
Ryan, William F. ;
Garces, Yolanda I. ;
Pu, Anthony T. ;
Singh, Anurag K. ;
Videtic, Gregory M. ;
McGarry, Ronald C. ;
Iyengar, Puneeth ;
Pantarotto, Jason R. ;
Urbanic, James J. ;
Sun, Alexander Y. ;
Daly, Megan E. ;
Grills, Inga S. ;
Sperduto, Paul ;
Normolle, Daniel P. ;
Bradley, Jeffrey D. ;
Choy, Hak .
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15) :1316-+
[5]   Stereotactic ablative radiotherapy (SABR) for treatment of central and ultra-central lung tumors [J].
Chaudhuri, Aadel A. ;
Tang, Chad ;
Binkley, Michael S. ;
Jin, Michelle ;
Wynne, Jacob F. ;
von Eyben, Rie ;
Hara, Wendy Y. ;
Trakul, Nicholas ;
Loo, Billy W., Jr. ;
Diehn, Maximilian .
LUNG CANCER, 2015, 89 (01) :50-56
[6]   An application of changepoint methods in studying the effect of age on survival in breast cancer [J].
Contal, C ;
O'Quigley, J .
COMPUTATIONAL STATISTICS & DATA ANALYSIS, 1999, 30 (03) :253-270
[7]   SUNSET: Stereotactic Radiation for Ultracentral Non-Small-Cell Lung Cancer-A Safety and Efficacy Trial [J].
Giuliani, Meredith ;
Mathew, Ashwathy S. ;
Bahig, Houda ;
Bratman, Scott V. ;
Filion, Edith ;
Glick, Daniel ;
Louie, Alexander V. ;
Raman, Srinivas ;
Swaminath, Anand ;
Warner, Andrew ;
Yau, Vivian ;
Palma, David .
CLINICAL LUNG CANCER, 2018, 19 (04) :E529-E532
[8]   Applicability of the linear-quadratic formalism for modeling local tumor control probability in high dose per fraction stereotactic body radiotherapy for early stage non-small cell lung cancer [J].
Guckenberger, Matthias ;
Klement, Rainer Johannes ;
Allgaeuer, Michael ;
Appold, Steffen ;
Dieckmann, Karin ;
Ernst, Iris ;
Ganswindt, Ute ;
Holy, Richard ;
Nestle, Ursula ;
Nevinny-Stickel, Meinhard ;
Semrau, Sabine ;
Sterzing, Florian ;
Wittig, Andrea ;
Andratschke, Nicolaus ;
Flentje, Michael .
RADIOTHERAPY AND ONCOLOGY, 2013, 109 (01) :13-20
[9]   Fatal complications after stereotactic body radiation therapy for central lung tumors abutting the proximal bronchial tree [J].
Haseltine, Justin M. ;
Rimner, Andreas ;
Gelblum, Daphna Y. ;
Modh, Ankit ;
Rosenzweig, Kenneth E. ;
Jackson, Andrew ;
Yorke, Ellen D. ;
Wu, Abraham J. .
PRACTICAL RADIATION ONCOLOGY, 2016, 6 (02) :E27-E33
[10]   The Nordic HILUS-Trial - First Report of a Phase II Trial of SBRT of Centrally Located Lung Tumors [J].
Lindberg, Karin ;
Bergstrom, Per ;
Brustugun, Odd Terje ;
Engelholm, Silke ;
Grozman, Vitali ;
Hoyer, Morten ;
Karlsson, Kristin ;
Khalil, Azza ;
Kristiansen, Charlotte ;
Lax, Ingmar ;
Loden, Britta ;
Nyman, Jan ;
Persson, Gitte ;
Rogg, Lotte ;
Wersall, Peter ;
Lewensohn, Rolf .
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) :S340-S340